Full-Time
Data Scientist
Commercial
Updated on 9/9/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
Bachelor's, Master's
 Data & Analytics (1) |
|---|
Get referred to Amgen
See people who can refer or advise you
- A Bachelor's or Master's degree in Data Science, Engineering, Statistics, or a related quantitative field is required.
- Three to five years of experience in analytics, modeling, or data science delivery is required.
- Working knowledge of Python and SQL, with comfort working in Databricks or similar environments, is required.
- Experience with data visualization and performance metric tracking is required.
- The candidate must demonstrate strong attention to detail and a focus on delivering high-quality, reproducible work.
- Support the execution of analytics and modeling projects across therapeutic area delivery and/or investment analytics teams.
- Assist in data preparation, exploratory analysis, metric tracking, and performance reporting with high accuracy.
- Help maintain and operationalize dashboards or reusable code assets in Databricks or Python/SQL environments.
- Partner with senior data scientists and leads on model building, testing, and result summaries.
- Support documentation, version control, and deployment practices using standardized platforms and tools.
- Exposure to marketing mix modeling, predictive modeling, or experiment-based analytics.
- Interest in life sciences, healthcare, or pharmaceutical analytics environments.
- Familiarity with MLflow, Git, or Jupyter notebooks.
- Ability to collaborate with analysts, engineers, or business partners to complete work.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $10.1 billion, and guidance rose to $38.2-$39.4 billion.
- Repatha sales jumped 37% to $953 million, with Uplizna up 90%.
- A federal judge blocked Colorado's Enbrel cap, preserving U.S. pricing flexibility.
What critics are saying
- FDA proposed withdrawing Tavneos on April 27, 2026, after data manipulation findings.
- Novartis pelacarsen failed Phase 3 in 2026, raising Amgen's olpasiran outcomes bar.
- Colorado's Enbrel price-cap fight continues on appeal, threatening legacy cash flow through 2027.
What makes Amgen unique
- Repatha, Evenity, Uplizna, and Tezspire diversify growth beyond Enbrel and Prolia.
- Amgen's 7,297-patient OCEAN(a)-Outcomes gives olpasiran a large cardiovascular readout.
- Hyderabad's Genome Valley center expands Amgen's R&D footprint with data-driven discovery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.
Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.
Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.
Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.
Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.